Development and Validation of an Interpretable Machine Learning Model for Predicting Early Pulmonary Metastasis Risk in Osteosarcoma
Cancer Medicine · 2026
DOI: 10.1002/cam4.72209 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Jianhua Mu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Orthopeadic Research Institute, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, Chin…. Hauptthemen laut MEDLINE: Osteosarcoma, Lung Neoplasms, Bone Neoplasms, Machine Learning. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction
Pulmonary metastasis in high‐grade conventional osteosarcoma remains a leading cause of treatment failure and mortality. Traditional monitoring methods are insufficient for early detection. This study aims to develop and validate an interpretable machine learning (ML) model using multi‐dimensional data from electronic medical records (EMR) to predict the early risk of pulmonary metastasis in high‐grade conventional osteosarcoma patients.
Methods
This retrospective study included data from 522 high‐grade conventional osteosarcoma patients. After rigorous feature selection, 12 independent predictive factors were identified: prothrombin time (PT), international normalized ratio (INR), fibrinogen, globulin, prognostic nutritional index (PNI), eosinophil percentage, monocyte percentage, neutrophil percentage, monocyte count, maximum tumor diameter, gender, and amputation status. Eleven ML models were constructed and compared, with Shapley Additive Explanations (SHAP) analysis applied to enhance model interpretability and clinical transparency.
Results
The gradient boosting model exhibited superior performance, achieving an area under the curve (AUC) of 0.891 in the training set and 0.742 in the independent test set. SHAP analysis revealed that tumor maximum diameter was the most influential predictor of pulmonary metastasis risk, while inflammation and coagulation‐related indicators also demonstrated significant contributions.
Discussion
The gradient boosting model effectively predicts the early risk of pulmonary metastasis in high‐grade conventional osteosarcoma and provides interpretable risk factors. This model shows potential as a clinical decision support tool, facilitating personalized risk management and precision medicine, aiming to improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedics, Orthopeadic Research Institute, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China.
- Model Worker and Craftsman Talent Innovation Workshop of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Jianhua Mu, Han Liu, Zhuangzhuang Li, Yi Luo, Li Min, Chongqi Tu
Förderung
- Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Mu, J., Wang, Y., Liu, H., He, X., Li, Z., Luo, Y., Zhou, Y., Lu, M., Tang, F., Min, L., & Tu, C. (2026). Development and Validation of an Interpretable Machine Learning Model for Predicting Early Pulmonary Metastasis Risk in Osteosarcoma. Cancer Medicine. https://doi.org/10.1002/cam4.72209
Vancouver
Mu J, Wang Y, Liu H, He X, Li Z, Luo Y, et al. Development and Validation of an Interpretable Machine Learning Model for Predicting Early Pulmonary Metastasis Risk in Osteosarcoma. Cancer Medicine. 2026. doi:10.1002/cam4.72209
BibTeX
@article{Mu2026,
author = {Mu, Jianhua and Wang, Yitian and Liu, Han and He, Xuanhong and Li, Zhuangzhuang and Luo, Yi and Zhou, Yong and Lu, Minxun and Tang, Fan and Min, Li and Tu, Chongqi},
title = {Development and Validation of an Interpretable Machine Learning Model for Predicting Early Pulmonary Metastasis Risk in Osteosarcoma},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72209}
}
EUVIMED